Clinical Study Finds Combining Patient Risk Stratification With EarlySense Continuous Monitoring can Reduce Clinician Work Load and Improve Patient Sleep and Satisfaction
WOBURN, Massachusetts, March 26, 2019 /PRNewswire/ — EarlySense, the market leader in contact-free continuous monitoring solutions across the care continuum, announced today the results of a randomized controlled clinical study conducted at the University of Chicago, which found significant benefit to low-risk patients who are not woken during the night for vital sign assessments.
The study found that low-risk hospitalized patients undisturbed by staff between 11 p.m. and 6 a.m. slept better and reported increased satisfaction with the care they received from nurses during hospitalization. These patients also incurred no additional deterioration or adverse events, versus the control group. A secondary analysis estimated the potential cost savings, due to reduction in overnight staff workload by avoiding nighttime vital sign checks, to be in the range of approximately $200,000 to $550,000 per 100 hospital beds per year.
Sleep disruptions for routine care are common during hospitalization and are associated with negative health outcomes and reduced patient satisfaction. In the study, clinical staff avoided nighttime checkups on patients deemed low-risk by their 10 p.m. risk score. All patients participating in the study were monitored by EarlySense’s under the mattress, contact-free continuous monitoring device to keep them safe without waking them. This allowed clinicians – freed from additional vital sign collection – to focus on additional areas of patient care.
“In this study, we were able to accurately identify low-risk patients and avoid waking them at night, with the safety net of continuous vital sign monitoring,” said Dr. Dana Edelson, MD, the study’s Principal Investigator. “This practice represents a simple, patient-centered approach to deploying expensive healthcare resources which improves patient satisfaction and decreases costs without increasing risk. Letting our low risk patients sleep at night is an easy win and should be the new standard of care.”
“One of the key challenges of modern health systems is that a large number of patients undergo unnecessary, costly and disruptive clinical assessments. By combining contact-free monitoring and patient risk stratification, hospitals can achieve a triple win: reduced clinician work load, improved patient safety and healing (via better sleep), and increased patient satisfaction. Providing hospitals with the tools and technologies necessary to keep patients safe and healthy while reducing costs has been our goal from the very beginning,” said Avner Halperin, CEO and Co-founder of EarlySense. “Dr. Edelson continues to push the envelope of medical innovation, and we are pleased to collaborate with her to bring the most advanced cost saving solutions to hospitals to elevate patient care.”
About EarlySense
EarlySense® is the global leader in contact-free, continuous monitoring solutions for the healthcare continuum. Used worldwide in hospitals, post-acute care facilities, and homes, EarlySense assists clinicians in early detection of patient deterioration. The solution has been proven to help prevent adverse events, including code blue events which are a result of cardiac or respiratory arrest, preventable ICU transfers, patient falls, pressure ulcers, and hospital readmissions. EarlySense’s FDA-cleared solutions leverage Artificial Intelligence (AI) and big data analytics to provide actionable health insights and improve clinical outcomes. The company has partnered with leading global technology companies including Hill-Rom, Philips, Welch Allyn, Mitsui and Beurer. EarlySense is based in Ramat Gan, Israel and Woburn, Massachusetts. For more information, visit www.earlysense.com.
Follow EarlySense on LinkedIn, Twitter and Facebook.
Media Contact:
Goel Jasper
Finn Partners
+1-929-222-8002
goel.jasper@finnpartners.com
Company Contact::
Hila Peleg
+972-54-527-3117
hila.peleg@earlysense.com
SOURCE EarlySense